PATENT APPLICATION

SYSTEMS AND COMPUTER SOFTWARE PRODUCTS FOR GENE EXPRESSION ANALYSIS

Inventors:

Wei-min Liu
a citizen of the United States of America
Residing at 2435 Fenian Dr.
Campbell, CA 95008

Rui Mei
A citizen of the United States of America
Residing at 234 Rodonovan Dr.
Santa Clara, CA 95051

Thomas B. Ryder
A citizen of the United States of America
Residing at 100 Spring Street
Los Gatos, CA, 95030

Assignee:

Affymetrix, Inc.
a Corporation Organized under the laws of Delaware

Entity:

Large

Legal Department
Affymetrix, Inc.
3380 Central Expressway
Santa Clara, CA 95051
(408) 731-5000

SYSTEMS AND COMPUTER SOFTWARE PRODUCTS
FOR GENE EXPRESSION ANALYSIS

RELATED APPLICATIONS

5   This application claims the priority of U.S. Provisional Application Number

60/189,558, filed on March 15, 2000. The '558 application is incorporated herein by

reference in its entirety for all purposes.

FIELD OF INVENTION

10   This invention is related to bioinformatics and biological data analysis.

Specifically, this invention provides methods, computer software products and systems

for the analysis of biological data.

BACKGROUND OF THE INVENTION

Many biological functions are carried out by regulating the expression levels of

15   various genes, either through changes in the copy number of the genetic DNA, through

changes in levels of transcription (*e.g.* through control of initiation, provision of RNA

precursors, RNA processing, *etc.*) of particular genes, or through changes in protein

synthesis. For example, control of the cell cycle and cell differentiation, as well as

diseases, are characterized by the variations in the transcription levels of a group of genes.

20   Recently, massive parallel gene expression monitoring methods have been

developed to monitor the expression of a large number of genes using nucleic acid array

technology which was described in detail in, for example, U.S. Patent Number 5,871,928;

de Saizieu, *et al.*, 1998, Bacteria Transcript Imaging by Hybridization of total RNA to

Oligonucleotide Arrays, NATURE BIOTECHNOLOGY, 16:45-48; Wodicka *et al.*, 1997,

Genome-wide Expression Monitoring in *Saccharomyces cerevisiae*, NATURE

BIOTECHNOLOGY 15:1359-1367; Lockhart *et al.,* 1996, Expression Monitoring by

Hybridization to High Density Oligonucleotide Arrays. NATURE BIOTECHNOLOGY

14:1675-1680; Lander, 1999, Array of Hope, NATURE-GENETICS, 21(suppl.), at 3.

5   Massive parallel gene expression monitoring experiments generate unprecedented

amounts of information. For example, a commercially available GeneChip® array set is

capable of monitoring the expression levels of approximately 6,500 murine genes and

expressed sequence tags (ESTs) (Affymetrix, Inc, Santa Clara, CA, USA). Array sets for

approximately 60,000 human genes and EST clusters, 24,000 rat transcripts and EST

10   clusters and arrays for other organisms are also available from Affymetrix. Effective

analysis of the large amount of data may lead to the development of new drugs and new

diagnostic tools. Therefore, there is a great demand in the art for methods for organizing,

accessing and analyzing the vast amount of information collected using massive parallel

gene expression monitoring methods.

15   **SUMMARY OF THE INVENTION**

The current invention provides methods, systems and computer software products

suitable for analyzing data from gene expression monitoring experiments that employ

multiple probes against a single target.

In one aspect of the invention, non-parametric statistical analysis is employed to

20   analyze results of multiple probe gene expression experiments with control probes such

as mismatch probes.   In some embodiments, each target sub-region of a transcript is

detected using two probes. One of probes is a perfect match (PM) probe that is designed

to be completely complementary to a reference or target transcript. A mismatch (MM) probe is a probe that is designed to be complementary to a reference sequence except for some mismatches that may significantly affect the hybridization between the probe and its target sequence. In preferred embodiments, MM probes are designed to be

5   complementary to a reference sequence except for a homomeric base mismatch at the central (e.g., 13th in a 25 base probe) position. Mismatch probes are normally used as controls for cross-hybridization. A probe pair is usually composed of a PM and its corresponding MM probe. The difference between PM and MM provides an intensity difference in a probe pair.

10   In one aspect of the invention, computer implemented methods are used for determining whether a transcript is present in a biological sample. The methods include step of providing a plurality of perfect match intensity values (PM_i) and mismatch intensity values (MM_i) for the transcript, where each of the PM_i is paired with one of the MM_i; calculating a p-value using one sided Wilcoxon's signed rank test, where the p-

15   value is for a null hypothesis that θ=a threshold value and an alternative hypothesis that said θ> the threshold value, wherein said θ is a test statistic for intensity difference between the perfect match intensity values and mismatch intensity values; and indicating whether the transcript is present based upon the p-value.

In some embodiments, the testing statistic is $median(PM_i\text{-}MM_i)$. The threshold

20   value may be zero. In some preferred embodiments, the threshold value is calculated using $\tau_1 = c_1 \sqrt{median(PM_i)}$ wherein said c_1 is a constant. Alternatively, the threshold value is calculated using: $\tau_1 = c_1 \sqrt{mean(PM_i)}$ wherein c_1 is a constant.

The presence, marginal present or absence (detected, marginally detected or undetected) of a transcript may be called based upon the p –value and significance levels. Significance levels, α_1 and α_2 may be set such that: $0<\alpha_1<\alpha_2<0.5$. Note that for the one-sided test, if null hypothesis is true, the most likely observed p-value is 0.5, which is

5 equivalent to 1 for the two-sided test. Let p be the p-value of one sided signed rank test. In preferred embodiments, if $p<\alpha_1$, a "detected" call can be made (i.e., the expression of the target gene is detected in the sample). If $\alpha_1 \leq p <\alpha_2$, a marginally detected call may be made. If $p \geq \alpha_2$, "undetected call" may be made. The proper choice of significance levels and the thresholds can reduce false calls. In some preferred embodiments,

10 $0<\alpha_1<\alpha_2<0.06$. In some particularly preferred embodiments, α_1 is around 0.04 and α_2 is around 0.06.

In some particularly preferred embodiments, the testing statistic is $median((PM_i-MM_i)/(PM_i=MM_i))$. In these embodiments, the threshold value is a constant. Typically, the threshold value is around 0.001 to 0.05. Most preferably, the threshold value is

15 around 0.015.

In another aspect of the invention, computer implemented methods are provided for analyzing gene expression experiments where a transcript is detected with multiple probes. The method include steps of providing a plurality of perfect match intensity values (PM_i) and background intensity values (B_i) for the transcript, where each of the

20 PM_i is paired with its corresponding B_i; calculating a p value using one sided Wilcoxon's signed rank test, wherein the p value is for a null hypothesis that $\theta=$a threshold value and an alternative hypothesis that the $\theta>$ the threshold value, where the θ is a test statistic for

intensity difference between the perfect match intensity values and background intensity values; and indicating whether the transcript is present based upon the p-value. In preferred embodiments, the testing statistic is *median(PM_i-B_i)*.

The threshold value can be zero. However, in preferred embodiments, the

5   threshold value is calculated using $\tau_3 = c_3\sqrt{median(PM_i)}$ where the c_l is a constant.

Alternatively, the threshold value is calculated using: $\tau_3 = c_3\sqrt{mean(PM_i)}$ where the c_3

is a constant.

The presence, marginal present or absence (detected, marginally detected or undetected) of a transcript may be called based upon the p–value and significance levels.

10   Significance levels, α_1 and α_2 may be set such that: $0<\alpha_1<\alpha_2<0.5$. Note that for the one-sided test, if null hypothesis is true, the most likely observed p-value is 0.5, which is equivalent to 1 for the two-sided test. Let p be the p-value of one-sided signed rank test. In preferred embodiments, if $p<\alpha_1$, a "detected" call can be made (i.e., the expression of the target gene is detected in the sample). If $\alpha_1 \leq p <\alpha_2$, a marginally detected call may be

15   made. If $p \geq \alpha_2$, "undetected call" may be made. The proper choice of significance levels and the thresholds can reduce false calls. In some preferred embodiments, $0<\alpha_1<\alpha_2<0.06$. In some particularly preferred embodiments, α_1 is around 0.04 and α_2 is around 0.06.

In another aspect, computer software products are provided. The computer

20   software products include computer program code for inputting a plurality of perfect match intensity values (*PM_i*) and mismatch intensity values (*MM_i*) for a transcript, wherein each of the *PM_i* is paired with one of the *MM_i*; computer program code for

calculating a p value using one-sided Wilcoxon's signed rank test, wherein the p value is for a null hypothesis that θ=a threshold value and an alternative hypothesis that the $\theta>$ the threshold value, wherein the θ is a test statistic for intensity difference between the perfect match intensity values and mismatch intensity values; computer program code for

5 indicating whether the transcript is present based upon the p value; and a computer readable media for storing the computer program codes. In some preferred embodiments of the computer software products, the testing statistic is $median(PM_i-MM_i)$. The threshold value may be zero in some embodiments. In preferred embodiments, however, the threshold value is calculated using $\tau_1 = c_1\sqrt{median(PM_i)}$ where the c_1 is a constant

10 or using $\tau_1 = c_1\sqrt{mean(PM_i)}$ where the c_1 is a constant.

In some particularly preferred embodiments of the computer software products of the invention, the testing statistic is $median((PM_i-MM_i)/(PM_i-MM_i))$ and threshold value is a constant. The computer program product may contain code for accepting user's selection or input of the threshold value. A default value may be used as well.

15 Typically, the threshold value is around 0.001 to 0.05. In a particularly preferred embodiment, the threshold value is around 0.015.

The presence, marginal present or absence (detected, marginally detected or undetected) of a transcript may be called based upon the p –value and significance levels. Significance levels, α_1 and α_2 may be set such that: $0<\alpha_1<\alpha_2<0.5$. In preferred

20 embodiments, if $p<\alpha_1$, a "detected" call can be made (i.e., the expression of the target gene is detected in the sample). If $\alpha_1 \leq p <\alpha_2$, a marginally detected call may be made. If $p\geq\alpha_2$, "undetected call" may be made. The proper choice of significance levels and the

thresholds can reduce false calls. In some preferred embodiments, $0<\alpha_1<\alpha_2<0.06$. In some particularly preferred embodiments, α_1 is around 0.04 and α_2 is around 0.06.

The computer software product may include computer program code for indicating that the transcript is present, absent or marginally absent . The computer program code, when executed, may indicate the result by causing the display of the result on a display device such as a screen. Alternatively, the result may be outputted into a file. In addition, the result may be temporary stored in a computer memory device so that other computer program module may access this result. In some preferred embodiments, the computer software products may include code to accept user's selection of various significance levels.

In addition, the present invention includes computer software products for analyzing the presence of a transcript without using mismatch intensities. The computer software product includes computer program code for providing a plurality of perfect match intensity values (PM_i) and background intensity values (B_i) for a transcript, wherein each of the PM_i is paired with one of the B_i; computer program code for calculating a p-value using one-sided Wilcoxon's signed rank test, wherein said p-value is for a null hypothesis that θ=a threshold value and an alternative hypothesis that the $\theta>$ the threshold value, where the θ is a test statistic for intensity difference between the perfect match intensity values and background intensity values; and computer program code for indicating whether the transcript is present based upon the p-value; and a computer readable media for storing the codes. The testing statistic may be $median(PM_i-B_i)$. The threshold value can be zero.

In preferred embodiments, the threshold value is calculated using:

$\tau_3 = c_3 \sqrt{median(PM_i)}$ where the c_3 is a constant and alternatively, the threshold value is

calculated using: $\tau_3 = c_3 \sqrt{mean(PM_i)}$ where the c_3 is a constant.

5   The computer software product may include computer program code for

indicating that the transcript is present, absent or marginally absent . The computer

program code, when executed, may indicate the result by causing the display of the result

on a display device such as a screen. Alternatively, the result may be outputted into a file.

In addition, the result may be temporary stored in a computer memory device so that other

10   computer program module may access this result. In some preferred embodiments, the

computer software products may include code to accept user's selection of various

significance levels.

In addition, systems for determining whether a transcript is present in a biological

sample are also provided. The systems include a processor; and a memory being coupled

15   to the processor, the memory storing a plurality machine instructions that cause the

processor to perform a plurality of logical steps when implemented by the processor; the

logical steps include the method steps of the invention.

20

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and form a part of this specification, illustrate embodiments of the invention and, together with the description, serve to explain the principles of the invention:

5 Figure 1 illustrates an example of a computer system that may be utilized to execute the software of an embodiment of the invention.

Figure 2 illustrates a system block diagram of the computer system of Fig. 1.

Figure 3 is a schematic showing a set of probes with 20 probe pairs.

Figure 4 is a schematic showing a computerized method for detecting transcript.

10 Figure 5 is a schematic showing a process for detecting a transcript using a statistic *median* (PM_i-MM_i).

Figure 6 is a schematic showing a process for detecting a transcript using a statistic *median*$((PM_i-MM_i)/ (PM_I+MM_i))$.

Figure 7 is a schematic showing a process for detecting a transcript without using

15 mismatch intensity values,

Figure 8 is a schematic showing a process for detecting a large number of transcripts.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

20 Reference will now be made in detail to the preferred embodiments of the invention. While the invention will be described in conjunction with the preferred embodiments, it will be understood that they are not intended to limit the invention to

these embodiments. On the contrary, the invention is intended to cover alternatives,

modifications and equivalents, which may be included within the spirit and scope of the

invention. All cited references, including patent and non-patent literature, are

incorporated herein by reference in their entireties for all purposes.

5

I. Gene Expression Monitoring With High Density Oligonucleotide Probe Arrays

High density nucleic acid probe arrays, also referred to as "DNA Microarrays,"

have become a method of choice for monitoring the expression of a large number of

genes. As used herein, "Nucleic acids" may include any polymer or oligomer of

10   nucleosides or nucleotides (polynucleotides or oligonucleotidies), which include

pyrimidine and purine bases, preferably cytosine, thymine, and uracil, and adenine and

guanine, respectively. See Albert L. Lehninger, PRINCIPLES OF BIOCHEMISTRY, at

793-800 (Worth Pub. 1982) and L. Stryer BIOCHEMISTRY, 4th Ed., (March 1995), both

incorporated by reference. "Nucleic acids" may include any deoxyribonucleotide,

15   ribonucleotide or peptide nucleic acid component, and any chemical variants thereof,

such as methylated, hydroxymethylated or glucosylated forms of these bases, and the like.

The polymers or oligomers may be heterogeneous or homogeneous in composition, and

may be isolated from naturally-occurring sources or may be artificially or synthetically

produced. In addition, the nucleic acids may be DNA or RNA, or a mixture thereof, and

20   may exist permanently or transitionally in single-stranded or double-stranded form,

including homoduplex, heteroduplex, and hybrid states.

11

"A target molecule" refers to a biological molecule of interest. The biological molecule of interest can be a ligand, receptor, peptide, nucleic acid (oligonucleotide or polynucleotide of RNA or DNA), or any other of the biological molecules listed in U.S. Patent No. 5,445,934 at col. 5, line 66 to col. 7, line 51. For example, if transcripts of

5   genes are the interest of an experiment, the target molecules would be the transcripts. Other examples include protein fragments, small molecules, etc. "Target nucleic acid" refers to a nucleic acid (often derived from a biological sample) of interest. Frequently, a target molecule is detected using one or more probes. As used herein, a "probe" is a molecule for detecting a target molecule. It can be any of the molecules in the same

10   classes as the target referred to above. A probe may refer to a nucleic acid, such as an oligonucleotide, capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e. A, G, U, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In

15   addition, the bases in probes may be joined by a linkage other than a phosphodiester bond, so long as the bond does not interfere with hybridization. Thus, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. Other examples of probes include antibodies used to detect peptides or other molecules, any ligands for detecting its binding partners. When

20   referring to targets or probes as nucleic acids, it should be understood that there are illustrative embodiments that are not to limit the invention in any way.

In preferred embodiments, probes may be immobilized on substrates to create an array. An "array" may comprise a solid support with peptide or nucleic acid or other molecular probes attached to the support. Arrays typically comprise a plurality of different nucleic acids or peptide probes that are coupled to a surface of a substrate in

5   different, known locations. These arrays, also described as "microarrays" or colloquially "chips" have been generally described in the art, for example, in Fodor et al., Science, 251:767-777 (1991), which is incorporated by reference for all purposes. Methods of forming high density arrays of oligonucleotides, peptides and other polymer sequences with a minimal number of synthetic steps are disclosed in, for example, 5,143,854,

10   5,252,743, 5,384,261, 5,405,783, 5,424,186, 5,429,807, 5,445,943, 5,510,270, 5,677,195, 5,571,639, 6,040,138, all incorporated herein by reference for all purposes. The oligonucleotide analogue array can be synthesized on a solid substrate by a variety of methods, including, but not limited to, light-directed chemical coupling, and mechanically directed coupling. See Pirrung et al., U.S. Patent No. 5,143,854 (see also

15   PCT Application No. WO 90/15070) and Fodor et al., PCT Publication Nos. WO 92/10092 and WO 93/09668, U.S. Pat. Nos. 5,677,195, 5,800,992 and 6,156,501 which disclose methods of forming vast arrays of peptides, oligonucleotides and other molecules using, for example, light-directed synthesis techniques. See also, Fodor et al., Science, 251, 767-77 (1991). These procedures for synthesis of polymer arrays are now referred to

20   as VLSIPS™ procedures. Using the VLSIPS™ approach, one heterogeneous array of polymers is converted, through simultaneous coupling at a number of reaction sites, into a different heterogeneous array. See, U.S. Patent Nos. 5,384,261 and 5,677,195.

Methods for making and using molecular probe arrays, particularly nucleic acid

probe arrays are also disclosed in, for example, U.S. Patent Numbers 5,143,854,

5,242,974, 5,252,743, 5,324,633, 5,384,261, 5,405,783, 5,409,810, 5,412,087, 5,424,186,

5,429,807, 5,445,934, 5,451,683, 5,482,867, 5,489,678, 5,491,074, 5,510,270, 5,527,681,

5   5,527,681, 5,541,061, 5,550,215, 5,554,501, 5,556,752, 5,556,961, 5,571,639, 5,583,211,

5,593,839, 5,599,695, 5,607,832, 5,624,711, 5,677,195, 5,744,101, 5,744,305, 5,753,788,

5,770,456, 5,770,722, 5,831,070, 5,856,101, 5,885,837, 5,889,165, 5,919,523, 5,922,591,

5,925,517, 5,658,734, 6,022,963, 6,150,147, 6,147,205, 6,153,743, 6,140,044 and

D430024, all of which are incorporated by reference in their entireties for all purposes.

10   Typically, a nucleic acid sample is a labeled with a signal moiety, such as a fluorescent

label. The sample is hybridized with the array under appropriate conditions. The arrays

are washed or otherwise processed to remove non-hybridized sample nucleic acids. The

hybridization is then evaluated by detecting the distribution of the label on the chip. The

distribution of label may be detected by scanning the arrays to determine florescence

15   intensities distribution. Typically, the hybridization of each probe is reflected by several

pixel intensities. The raw intensity data may be stored in a gray scale pixel intensity file.

The GATC™ Consortium has specified several file formats for storing array intensity

data. The final software specification is available at www.gatcconsortium.org and is

incorporated herein by reference in its entirety. The pixel intensity files are usually large.

20   For example, a GATC™ compatible image file may be approximately 50 Mb if there are

about 5000 pixels on each of the horizontal and vertical axes and if a two byte integer is

used for every pixel intensity. The pixels may be grouped into cells (see, GATC™

software specification). The probes in a cell are designed to have the same sequence (i.e., each cell is a probe area). A CEL file contains the statistics of a cell, e.g., the 75 percentile and standard deviation of intensities of pixels in a cell. The 75 percentile of pixel intensity of a cell is often used as the intensity of the cell. Methods for signal

5 detection and processing of intensity data are additionally disclosed in, for example, U.S. Patents Numbers 5,547,839, 5,578,832, 5,631,734, 5,800,992, 5,856,092, 5,936,324, 5,981,956, 6,025,601, 6,090,555, 6,141,096, 6,141,096, and 5,902,723. Methods for array based assays, computer software for data analysis and applications are additionally disclosed in, e.g., U.S. Patent Numbers 5,527,670, 5,527,676, 5,545,531, 5,622,829,

10 5,631,128, 5,639,423, 5,646,039, 5,650,268, 5,654,155, 5,674,742, 5,710,000, 5,733,729, 5,795,716, 5,814,450, 5,821,328, 5,824,477, 5,834,252, 5,834,758, 5,837,832, 5,843,655, 5,856,086, 5,856,104, 5,856,174, 5,858,659, 5,861,242, 5,869,244, 5,871,928, 5,874,219, 5,902,723, 5,925,525, 5,928,905, 5,935,793, 5,945,334, 5,959,098, 5,968,730, 5,968,740, 5,974,164, 5,981,174, 5,981,185, 5,985,651, 6,013,440, 6,013,449, 6,020,135, 6,027,880,

15 6,027,894, 6,033,850, 6,033,860, 6,037,124, 6,040,138, 6,040,193, 6,043,080, 6,045,996, 6,050,719, 6,066,454, 6,083,697, 6,114,116, 6,114,122, 6,121,048, 6,124,102, 6,130,046, 6,132,580, 6,132,996 and 6,136,269, all of which are incorporated by reference in their entireties for all purposes.

Nucleic acid probe array technology, use of such arrays, analysis array based

20 experiments, associated computer software, composition for making the array and practical applications of the nucleic acid arrays are also disclosed, for example, in the following U.S. Patent Applications: 07/838,607, 07/883,327, 07/978,940, 08/030,138,

08/082,937, 08/143,312, 08/327,522, 08/376,963, 08/440,742, 08/533,582, 08/643,822,

08/772,376, 09/013,596, 09/016,564, 09/019,882, 09/020,743, 09/030,028, 09/045,547,

09/060,922, 09/063,311, 09/076,575, 09/079,324, 09/086,285, 09/093,947, 09/097,675,

09/102,167, 09/102,986, 09/122,167, 09/122,169, 09/122,216, 09/122,304, 09/122,434,

5   09/126,645, 09/127,115, 09/132,368, 09/134,758, 09/138,958, 09/146,969, 09/148,210,

09/148,813, 09/170,847, 09/172,190, 09/174,364, 09/199,655, 09/203,677, 09/256,301,

09/285,658, 09/294,293, 09/318,775, 09/326,137, 09/326,374, 09/341,302, 09/354,935,

09/358,664, 09/373,984, 09/377,907, 09/383,986, 09/394,230, 09/396,196, 09/418,044,

09/418,946, 09/420,805, 09/428,350, 09/431,964, 09/445,734, 09/464,350, 09/475,209,

10   09/502,048, 09/510,643, 09/513,300, 09/516,388, 09/528,414, 09/535,142, 09/544,627,

09/620,780, 09/640,962, 09/641,081, 09/670,510, 09/685,011, and 09/693,204 and in the

following Patent Cooperative Treaty (PCT) applications/publications: PCT/NL90/00081,

PCT/GB91/00066, PCT/US91/08693, PCT/US91/09226, PCT/US91/09217,

WO/93/10161, PCT/US92/10183, PCT/GB93/00147, PCT/US93/01152, WO/93/22680,

15   PCT/US93/04145, PCT/US93/08015, PCT/US94/07106, PCT/US94/12305,

PCT/GB95/00542, PCT/US95/07377, PCT/US95/02024, PCT/US96/05480,

PCT/US96/11147, PCT/US96/14839, PCT/US96/15606, PCT/US97/01603,

PCT/US97/02102, PCT/GB97/005566, PCT/US97/06535, PCT/GB97/01148,

PCT/GB97/01258, PCT/US97/08319, PCT/US97/08446, PCT/US97/10365,

20   PCT/US97/17002, PCT/US97/16738, PCT/US97/19665, PCT/US97/20313,

PCT/US97/21209, PCT/US97/21782, PCT/US97/23360, PCT/US98/06414,

PCT/US98/01206, PCT/GB98/00975, PCT/US98/04280, PCT/US98/04571,

PCT/US98/05438, PCT/US98/05451, PCT/US98/12442, PCT/US98/12779,

PCT/US98/12930, PCT/US98/13949, PCT/US98/15151, PCT/US98/15469,

PCT/US98/15458, PCT/US98/15456, PCT/US98/16971, PCT/US98/16686,

PCT/US99/19069, PCT/US98/18873, PCT/US98/18541, PCT/US98/19325,

5   PCT/US98/22966, PCT/US98/26925, PCT/US98/27405 and PCT/IB99/00048, all of

which are incorporated by reference in their entireties for all purposes. All the above

cited patent applications and other references cited throughout this specification are

incorporated herein by reference in their entireties for all purposes.

The embodiments of the invention will be described using GeneChip® high

10   oligonucleotide density probe arrays (available from Affymetrix, Inc., Santa Clara, CA,

USA) as exemplary embodiments. One of skill the art would appreciate that the

embodiments of the invention are not limited to high density oligonucleotide probe

arrays. In contrast, the embodiments of the invention are useful for analyzing any parallel

large scale biological analysis, such as those using nucleic acid probe array, protein

15   arrays, etc.

Gene expression monitoring using GeneChip® high density oligonucleotide probe

arrays are described in, for example, Lockhart et al., 1996, Expression Monitoring By

Hybridization to High Density Oligonucleotide Arrays, Nature Biotechnology 14:1675-

1680; U.S. Patent Nos. 6,040,138 and 5,800,992, all incorporated herein by reference in

20   their entireties for all purposes.

In the preferred embodiment, oligonucleotide probes are synthesized directly on

the surface of the array using photolithography and combinatorial chemistry as disclosed

in several patents previous incorporated by reference. In such embodiments, a single square-shaped feature on an array contains one type of probe. Probes are selected to be specific against desired target. Methods for selecting probe sequences are disclosed in, for example, U.S. Patent Application Nos._____, Attorney Docket Number 3359;

5 _____, filed November 21, 2000, Attorney Docket Number 3367, filed November 21, 2000, and _____, Attorney Docket Number 3373, filed November 21, 2000, all incorporated herein by reference in their entireties for all purposes.

In a preferred embodiment, oligonucleotide probes in the high density array are selected to bind specifically to the nucleic acid target to which they are directed with

10 minimal non-specific binding or cross-hybridization under the particular hybridization conditions utilized. Because the high density arrays of this invention can contain in excess of 1,000,000 different probes, it is possible to provide every probe of a characteristic length that binds to a particular nucleic acid sequence. Thus, for example, the high density array can contain every possible 20 mer sequence complementary to an

15 IL-2 mRNA. There, however, may exist 20 mer subsequences that are not unique to the IL-2 mRNA. Probes directed to these subsequences are expected to cross hybridize with occurrences of their complementary sequence in other regions of the sample genome. Similarly, other probes simply may not hybridize effectively under the hybridization conditions (e.g., due to secondary structure, or interactions with the substrate or other

20 probes). Thus, in a preferred embodiment, the probes that show such poor specificity or hybridization efficiency are identified and may not be included either in the high density array itself (e.g., during fabrication of the array) or in the post-hybridization data analysis.

18

Probes as short as 15, 20, 25 or 30 nucleotides are sufficient to hybridize to a subsequence of a gene and that, for most genes, there is a set of probes that performs well across a wide range of target nucleic acid concentrations. In a preferred embodiment, it is desirable to choose a preferred or "optimum" subset of probes for each gene before

5   synthesizing the high density array.

In some preferred embodiments, the expression of a particular transcript may be detected by a plurality of probes, typically, up to 5, 10, 15, 20, 30 or 40 probes. Each of the probes may target different sub-regions of the transcript. However, probes may overlap over targeted regions.

10   In some preferred embodiments, each target sub-region is detected using two probes: a perfect match (PM) probe that is designed to be completely complementary to a reference or target sequence. In some other embodiments, a PM probe may be substantially complementary to the reference sequence. A mismatch (MM) probe is a probe that is designed to be complementary to a reference sequence except for some

15   mismatches that may significantly affect the hybridization between the probe and its target sequence. In preferred embodiments, MM probes are designed to be complementary to a reference sequence except for a homomeric base mismatch at the central (e.g., 13th in a 25 base probe) position. Mismatch probes are normally used as controls for cross-hybridization. A probe pair is usually composed of a PM and its

20   corresponding MM probe. The difference between PM and MM provides an intensity difference in a probe pair.

II.   Data Analysis Systems

In one aspect of the invention, methods, computer software products and systems are provided for computational analysis of microarray intensity data for determining the presence or absence of genes in a given biological sample. Accordingly, the present

5   invention may take the form of data analysis systems, methods, analysis software, etc. Software written according to the present invention is to be stored in some form of computer readable medium, such as memory, or CD-ROM, or transmitted over a network, and executed by a processor. For a description of basic computer systems and computer networks, see, e.g., Introduction to Computing Systems: From Bits and Gates to

10   C and Beyond by Yale N. Patt, Sanjay J. Patel, 1st edition (January 15, 2000) McGraw Hill Text; ISBN: 0072376902; and Introduction to Client/Server Systems : A Practical Guide for Systems Professionals by Paul E. Renaud, 2nd edition (June 1996), John Wiley & Sons; ISBN: 0471133337.

Computer software products may be written in any of various suitable

15   programming languages, such as C, C++, C# (Microsoft®), Fortran, Perl, MatLab (MathWorks, www.mathworks.com), SAS, SPSS and Java. The computer software product may be an independent application with data input and data display modules. Alternatively, the computer software products may be classes that may be instantiated as distributed objects. The computer software products may also be component software

20   such as Java Beans (Sun Microsystem), Enterprise Java Beans (EJB, Sun Microsystems), Microsoft® COM/DCOM (Microsoft®), etc.

Figure 1 illustrates an example of a computer system that may be used to execute
the software of an embodiment of the invention. Figure 1 shows a computer system 1
that includes a display 3, screen 5, cabinet 7, keyboard 9, and mouse 11. Mouse 11 may
have one or more buttons for interacting with a graphic user interface. Cabinet 7 houses a

5   CD-ROM or DVD-ROM drive 13, system memory and a hard drive (*see* Figure 2) which
may be utilized to store and retrieve software programs incorporating computer code that
implements the invention, data for use with the invention and the like. Although a CD 15
is shown as an exemplary computer readable medium, other computer readable storage
media including floppy disk, tape, flash memory, system memory, and hard drive may be

10   utilized. Additionally, a data signal embodied in a carrier wave (*e.g.,* in a network
including the Internet) may be the computer readable storage medium.

Figure 2 shows a system block diagram of computer system 1 used to execute the
software of an embodiment of the invention. As in Figure 1, computer system 1 includes
monitor 3, keyboard 9, and mouse 11. Computer system 1 further includes subsystems

15   such as a central processor 51, system memory 53, fixed storage 55 (*e.g.,* hard drive),
removable storage 57 (*e.g.,* CD-ROM), display adapter 59, sound card 61, speakers 63,
and network interface 65. Other computer systems suitable for use with the invention
may include additional or fewer subsystems. For example, another computer system may
include more than one processor 51 or a cache memory. Computer systems suitable for

20   use with the invention may also be embedded in a measurement instrument.

III.   Gene Expression Calls Using Non-Parametric Statistics

Computational analysis of probe array intensity data for determining the presence or absence of expression of genes in a given biological sample is a crucial step in extraction of useful information from experimental data.   There may be a large

5   uncertainty associated with these calls (i.e., determination of the presence or absence of the expression of genes) because of many random effects such as inevitable variations in manufacturing and experimental conditions, and the complexity of cross hybridization.

It is therefore desirable for every call to provide a p-value, the probability value for a testing statistic be equal or further extreme to its observed value under the null

10   hypothesis.

In one aspect of the invention, methods, computer software and systems are provided to determine (or call) the presence or absence of the expression of target genes using data from gene expression experiments that employ multiple probes against a single target.   The methods include steps for computing p-values of such calls using non-

15   parametric statistics.

Nonparametric statistical methods are powerful tools for computing exact p-values when the distribution of original data is unknown (e.g., Wilcoxon, F. *Individual Comparisons by Ranking Methods,* Biometrics, 1:80-83 (1945), Hogg RV, Tanis EA (1997) *Probability and Statistical Inference* (fifth edition), Upper Saddle River,

20   NJ:Prentice-Hall, Inc.; Hollander M, Wolfe DA (1999). *Nonparametric Statistical Methods* (second edition), New York: John Wiley & Sons, Inc., all incorporated herein by reference for all purposes).

22

Many nonparametric methods use ranks or signs of data, and hence are insensitive

to outliers. Their assumptions about the distributions of the original data are much

weaker than those of parametric methods. Therefore, they can be applied to more general

situations.

5   In some embodiments, Wilcoxon's signed rank test is used to analyze paired PM

and MM probes. In a block of n probe pairs (also known as atoms, Figure 3) for

detecting a gene (typically 10, 15, or 20 probe pairs). Each probe pair typically consists

of two cells, one has the sequence designed to be perfectly matching the target sequence

and the other has the sequence designed to be mismatching the target sequence,

10   preferrably at only a single nucleotide location (usually at the center of the sequence

segment).

Let the i-th perfectly matching cell intensity be PM_i and the i-th mismatching cell

intensity be MM_i ($i=1,....,n$). All these data are positive numbers. As described above, in

some embodiments, the hybridization of each probe may be reflected by several pixel

15   intensities. In such embodiments, the cell intensity is derived from the pixel intensities.

In preferred embodiments, around 60, 70, 75, 80, 85, or 90 percentile of of intensities of

inner pixels in a cell is used to represent the cell intensity. In a particularly preferred

embodiment, the 75 percentile of intensities of inner pixels in a cell is used to represent

the cell intensity and is saved in a CEL file together with the number of pixels and the

20   standard deviation of intensities at these pixels.

The traditional parametric approach to compare PM_i and MM_i is to test whether the mean of PM_i is equal to the mean of MM_i, or equivalently, whether the mean of differences

5
$$D_i = PM_i - MM_i \qquad (1)$$

is zero. To calculate the p-value, normal distribution is assumed.

The nonparametric approach, by contrast, is to test whether the median of PM_i is the same as the median of MM_i, or equivalently, whether the median of differences $D_i =$

10    $PM_i - MM_i$ is zero. In practice, it is better to include a positive threshold τ, and to test whether the median of D_i is larger than τ.

In practice, when using differences D_i, we require D_i be larger than a certain threshold τ to make a detected call. Using a threshold τ can avoid a detected call if most PM_i's are only slightly larger than MM_i's, which is possible sometimes when the gene is

15   really absent. In one embodiment, τ may be calculated as follows:

$$\tau = \frac{c}{2n} \sum_{j=1}^{2n} \frac{s_j}{\sqrt{n_j}}, \qquad (2)$$

Other statistics such as the discrimination score (also referred to as Ryder's discrimination score):

20

$$R_i = \frac{PM_i - MM_i}{PM_i + MM_i} \qquad (3)$$

can also be used. In spite of these different flavors of implementation, the principles of

computing p-values are the same. The methods of the invention involve the testing the

null hypothesis

5   H_0: median(D_i) = 0   (the gene is not expressed)

against the one-sided upper-tail alternative hypothesis

H_1: median(D_i) > 0.   (the gene is expressed)

10

Or more rigidly, assume D_i's ($i = 1, \ldots, n$) are from continuous populations, and are

mutually independent. Moreover, the distribution functions F_i's of D_i's are symmetric

about a common median θ, i.e.,

15
$$F_i(\theta + \chi) + F_i(\theta - \chi) = 1, \tag{4}$$

for all possible values of χ and i. The Wilcoxon's signed rank test can be used to test the

null hypothesis

20   H_0: $\theta = 0$

against the one-sided upper-tail alternative hypothesis

H_1: $\theta > 0$.

If all values if D_i's are zeros, then we accept the null hypothesis and let the p-value

5   be 0.5 for the one-sided test. If there are some but not all values of D_i's are zeros, then we

remove these zero values and adjust the block size n to be the number of nonzero D_i's that

are used for computing p-values.

Where there are no zero values of D_i's, all $|D_i|$'s are sorted in the ascending order.

If there are no ties among $|D_i|$'s, they can be ranked and assigned positive integers

10   1,2,...,n. Then, the signs of the original data are given to the ranks.

If there are ties of $|D_i|$'s the average of the consecutive integer ranks are assigned

to entries in a tied group. For example, consider six probe pairs with $D_1 = 150.2$, $D_2 =$

-300.1, $D_3 = 1700.1$, $D_4 = -150.2$, $D_5 = -50.3$, $D_6 = -50.3$. There are two tied groups: $|D_1| =$

$|D_4|$ and $|D_5| = |D_6|$. The signed ranks are $r_1 = 3.5$, $r_2 = -5$, $r_3 = 6$, $r_4 = 3.5$, $r_5 = -1.5$, and

15    $r_6 = -1.5$.

Let signed rank of D_i be r_i. The sum of all positive signed ranks may be

calculated as follows:

$$W_1+ = \sum_{i=1}^{n} c_i r_i, \qquad (5)$$

20   where the characteristic coefficient

$$c_i = \begin{cases} 1, & \text{if } r_i > 0, \\ 0, & \text{if } r_i < 0. \end{cases} \tag{6}$$

Under the null hypothesis, all 2^n possible patterns of signed ranks are uniformly distributed. Using this fact, the exact p-value for an observed W_1^+ statistic can be

5   calculated.

The computation of exact p-value becomes expensive when n is large. For large samples, under the null hypothesis, normal approximation for W_1^+ may be used, whose mean and variance are respectively

10

$$\mu_{W_1}^+ = \frac{n(n+1)}{4}, \tag{7}$$

$$V_{w_1}^+ = \frac{1}{24}\left[n(n+1)(2n+1) - \frac{1}{2}\sum_{k=1}^{g} t_k(t_k^2 - 1) \right], \tag{8}$$

where g is the number of tied groups, and t_k is the number of tied entries in tied group k.

Then the statistic

15

$$W_1^* = \frac{W_1^+ - \mu_{w_1}^+}{\sqrt{V_{w_1}^+}} \tag{9}$$

should approximately have the standard normal distribution $N(0,1)$.

27

Statistics other than $D_i = PM_i - MM_i$ can also be used for nonparametric methods.

For example, Ryder's discrimination score

$$R_i = \frac{PM_i - MM_i}{PM_i + MM_i} = 1 - \frac{2}{\frac{PM_i}{MM_i} + 1}. \tag{10}$$

5

is a monotonically increasing function of the ratio PM_i/MM_i. It changes the range $(0, \infty)$

of PM_i/MM_i to the range $(-1, 1)$ of R_i. In another embodiment, the following

discrimination score may be used:

10

$$L_i = \frac{PM_i - MM_i}{\sqrt{PM_i + MM_i}} \tag{11}$$

To compare the results of two experiments on the same chip, it is important to

determine a normalization factor. Let $PM_i^{(b)}$ and $MM_i^{(b)}$ be the intensity data of a

baseline experiment, and $PM_i^{(e)}$ and $MM_i^{(e)}$ be the intensity data of the other

experiment.

15   Wilcoxon's signed rank test can be applied to compare $PM_i^{(b)}$ with $N \cdot PM_i^{(e)}$.

$R_i^{(b)}$ may also be directly compared with $R_i^{(e)}$, Ryder's discrimination score of the baseline

experiment with that of the other experiment.

Other nonparametric methods can also be used to analyze microarray intensity

data. The CEL files give cell intensity which is the 75 percentile of pixel itensities in a

20   cell. When we want to reduce the number of probe sets in a block, using the DAT file to

take all pixel intensities into consideration may give more dependable analysis and more reasonable *p*-values.

In some particularly preferred embodiments, the following three statistics of cell intensities can be used to make calls based on one sided Wilcoxon's signed rank test. The null hypothesis is denoted H_0 and alternative hypothesis H_1.

(1) H_0: median $(PM_i - MM_i) = \tau_1$;

    H_1:median $(PM_i - MM_i) > \tau_1$

(2) H_0: median $(PM_i - MM_i)/ (PM_i + MM_i) = \tau_2$;

(10) H_1: median $(PM_i - MM_i)/ (PM_i - MM_i) > \tau_2$;

(3) H_0: median $(PM_i - B_i) = \tau_3$;

    H_1:median $(PM_i - B_i) > \tau_3$

Here, the threshold $\tau_1, \tau_2,$ and τ_3 are non-negative, and B_i in the third method is a space dependent background. Significance levels, α_1 and α_2 may be set such that:

$0 < \alpha_1 < \alpha_2 < 0.5$. Note that for the one-sided test, if null hypothesis is true, the most likely observed *p* value is 0.5, which is equivalent to 1 for the two-sided test. Let *p* be the *p*-value of one sided signed rank test. In preferred embodiments, if $p < \alpha_1$, a "detected" call can be made (i.e., the expression of the target gene is detected in the sample). If $\alpha_1 \le p < \alpha_2$, a marginally detected call may be made. If $p \ge \alpha_2$, "undetected call" may be made. The proper choice of significance levels and the thresholds can reduce false calls.

The threshold τ_1 may be set to be proportional to the square root of the sample median or mean of perfect match intensity, i.e.,

$$\tau_1 = c_1 \sqrt{median(PM_i)} \tag{13}$$

The Ryde discrimination score in the second test is a relative measure of the

difference between PM_i and MM_i. As discussed above, it is a monotonic function of

ratio: $r_i = \dfrac{PM_i}{MM_i}$, of perfect match and mismatch intensities:

5

$$R_i = (r_i - 1)/(r_i + 1) \tag{14}$$

Using the Ryder statistic is particularly preferred if both perfect match and mismatch

intensities are available. One benefit is that a constant τ_2 may be used to get good results.

Another justification of using a positive τ_2 is that the median of R_i is a small positive

number in several sets of Latin square experiments (Example 1, *infra*) with over 100

10   transcripts in each experiment with concentrations 0, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128,

256, 512, 1024 pM. Table 1 lists the median, 25 percentile, 75 percentile, minimum and

maximum of R_i in every concentration group. Table 2 is similar to Table 1, but with

human genome complex background. Both data are on chips with lot number 9912072.

When median (R_i) is below 0.7, corresponding approximately to the

15   concentration range below 30-60 pM or so, R_i increases when the concentration of the

transcript increases. Beyond this range, R_i may decrease as transcript concentration

increases, but remains higher than 0.7. Therefore, R_i is not always related to transcript

concentration, especially when median (R_i) is above 0.7, but for the purpose of absolute

calls, *i.e.*, to detect the existence of a gene above a small concentration, *e.g.*, 1 or 2 pM,

20   R_i is a very good statistic to use.

30

τ_2 may be set according user preference. In preferred embodiment, τ_2 may be set

at 0.005-0.05, preferably around 0.015, more preferably at 0.015. The third test, H_0:

median $(PM_i - B_i) = \tau_3$; H_1:median $(PM_i - B_i) > \tau_3$;

If mismatch intensities are not available, B_i can be considered as a background,

5   e.g., the average of the lowest 2 or the result of smoothing these averages. B_i so

calculated is usually lower than the mismatch intensities, but this can be made up by

adjusting τ_3. In some cases, τ_3 may be set to be proportional to the square root of the

sample median or mean of perfect match intensity, i.e.,

$$\tau_3 = c_3 \sqrt{median(PM_i)} \tag{15}$$

10

When a gene has splicing variants, a subset of atoms in a block can show

significant positive differences D_i, but within the whole block the differences may not be

so significantly different from 0. Nonparametric algorithms can detect this situation by

calculating the relevant statistics for subsets of a block of atoms.

15   The nonparametric algorithms suggested here need sorting. The results of sorting

subsets can be used for sorting the whole set with the merge sort algorithm. It can save

the total computing time for the detection of splicing variants with nonparametric

algorithms.

20   **IV.   Methods, Computer Software and Systems for Making Gene Expression**

Calls

In one aspect of the invention, computer implemented methods are provided for analyzing gene expression experiments. Figure 4 shows an exemplary process of the methods of the invention: Intensity data (such as perfect match intensities (PM_i) and mismatch intensities (MM_i) from the CEL file) are obtained (41) from data file (such as

5 the CEL file), directly from a measurement instrument (such as a scanner) or other data source. The intensity data are processed to calculate a p-value for the following hypotheses:H_0: $\theta = \tau$, H_1: $\theta > \tau$, where θ is a test statistic for intensity difference between the perfect match intensity values and the mismatch intensity values. The p-value is calculated using one-sided Wilcoxon's signed rank test.

10 In some embodiments (Figure 5), the testing statistic is $median(PM_i-MM_i)$ (53). The threshold value may be zero. In some preferred embodiments, the threshold value is calculated (52) using: $\tau_1 = c_1\sqrt{median(PM_i)}$ wherein said c_1 is a constant.

Alternatively, the threshold value is calculated using: $\tau_1 = c_1\sqrt{mean(PM_i)}$ wherein c_1 is a constant.

15 The presence\ marginal present or absence (detected, marginally detected or undetected) of a transcript may be called based upon the p–value and significance levels (54-58). Significance levels, α_1 and α_2 may be set such that: $0<\alpha_1<\alpha_2<0.5$. Note that for the one-sided test, if null hypothesis is true, the most likely observed p-value is 0.5, which is equivalent to 1 for the two-sided test. Let p be the p-value of one sided signed rank

20 test. In preferred embodiments, if $p<\alpha_1$, a "detected" call can be made (i.e., the expression of the target gene is detected in the sample). If $\alpha_1 \leq p <\alpha_2$, a marginally detected call may be made. If $p\geq\alpha_2$, "undetected call" may be made. The proper choice of significance

levels and the thresholds can reduce false calls. In some preferred embodiments, $0 < \alpha_1 < \alpha_2 < 0.06$. In some particularly preferred embodiments, α_1 is around 0.04 and α_2 is around 0.06.

In some particularly preferred embodiments (Figure 6), the testing statistic is

5    $median((PM_i-MM_i)/(PM_i-MM_i))$. In these embodiments, the threshold value is a constant. Typically, the threshold value is around 0.001 to 0.05. Most preferably, the threshold value is around 0.015.

In another aspect of the invention, computer implemented methods are provided for analyzing gene expression experiments where a transcript is detected with multiple

10   probes (Figure 7). The method include steps of providing a plurality of perfect match intensity values (PM_i) and background intensity values (B_i) for the transcript (71), where each of the PM_i is paired with its corresponding B_i; calculating a p value using one sided Wilcoxon's signed rank test, wherein the p value is for a null hypothesis that θ=a threshold value and an alternative hypothesis that the θ> the threshold value, where the θ

15   is a test statistic for intensity difference between the perfect match intensity values and background intensity values; and indicating whether the transcript is present based upon the p value. In preferred embodiments, the testing statistic is $median(PM_i-B_i)$ (74).

The threshold value can be zero. However, in preferred embodiments, the threshold value is calculated using: $\tau_1 = c_1\sqrt{median(PM_i)}$ where the c_1 is a constant.

20   Alternatively, the threshold value is calculated using: $\tau_3 = c_3\sqrt{mean(PM_i)}$ where the c_3 is a constant.

The presence, marginal present or absence (detected, marginally detected or undetected) of a transcript may be called based upon the p –value and significance levels. Significance levels, α_1 and α_2 may be set such that: $0<\alpha_1<\alpha_2<0.5$. Note that for the one-sided test, if null hypothesis is true, the most likely observed p value is 0.5, which is equivalent to 1 for the two-sided test. Let p be the p-value of one sided signed rank test. In preferred embodiments, if $p<\alpha_1$, a "detected" call can be made (i.e., the expression of the target gene is detected in the sample). If $\alpha_1 \leq p <\alpha_2$, a marginally detected call may be made. If $p\geq\alpha_2$, "undetected call" may be made. The proper choice of significance levels and the thresholds can reduce false calls. In some preferred embodiments, $0<\alpha_1<\alpha_2<0.06$. In some particularly preferred embodiments, α_1 is around 0.04 and α_2 is around 0.06.

The methods of the invention are particularly suitable for analyzing a large number of transcripts, preferably more than 50, 100, 500, 750, 1000, 2000, 3000, 5000, 10,000 or more. Figure 8 shows a process for detecting the presence of a large number of transcripts. In this embodiment, a library file which can be used to identify the relationship between probe sets and transcripts is read (81). Each of the probe sets may be targeting one transcript. An intensity data file contains intensity for a large number of probe sets (82), such as the CEL file, is also read. The p-value for each transcript is calculated (83, 84). The p-value of each transcript is used to detect the presence or absence of the transcript.

In another aspect, computer software products are provided. The computer software products include computer program code for inputting a plurality of perfect

34

match intensity values (PM_i) and mismatch intensity values (MM_i) for a transcript, wherein each of the PM_i is paired with one of the MM_i; computer program code for calculating a p-value using one-sided Wilcoxon's signed rank test, wherein the p-value is for a null hypothesis that $\theta=$ a threshold value and an alternative hypothesis that the $\theta>$

5   the threshold value, wherein the θ is a test statistic for intensity difference between the perfect match intensity values and mismatch intensity values; computer program code for indicating whether the transcript is present based upon the p-value; and a computer readable media for storing the computer program codes. In some preferred embodiments of the computer software products, the testing statistic is $median(PM_i\text{-}MM_i)$. The

10   threshold value may be zero in some embodiments. In preferred embodiments, however, the threshold value is calculated using: $\tau_1 = c_1\sqrt{median(PM_i)}$ where the c_1 is a constant

or using: $\tau_1 = c_1\sqrt{mean(PM_i)}$ where the c_1 is a constant.

In some particularly preferred embodiments of the computer software products of the invention, the testing statistic is $median((PM_i\text{-}MM_i)/(PM_i\text{-}MM_i))$ and threshold value

15   is a constant. The computer program product may contain code for accepting user's selection or input of the threshold value. A default value may be used as well. Typically, the threshold value is around 0.001 to 0.05. In a particularly preferred embodiment, the threshold value is around 0.015.

The presence, marginal present or absence (detected, marginally detected or

20   undetected) of a transcript may be called based upon the p –value and significance levels. Significance levels, α_1 and α_2 may be set such that: $0<\alpha_1<\alpha_2<0.5$. In preferred embodiments, if $p<\alpha_1$, a "detected" call can be made (i.e., the expression of the target

35

gene is detected in the sample). If $\alpha_1 \leq p < \alpha_2$, a marginally detected call may be made. If $p \geq \alpha_2$, "undetected call" may be made. The proper choice of significance levels and the thresholds can reduce false calls. In some preferred embodiments, $0 < \alpha_1 < \alpha_2 < 0.06$. In some particularly preferred embodiments, α_1 is around 0.04 and α_2 is around 0.06.

5　　The computer software product may include computer program code for indicating that the transcript is present, absent or marginally absent . The computer program code, when executed, may indicate the result by causing the display of the result on a display device such as a screen. Alternatively, the result may be outputted into a file. In addition, the result may be temporary stored in a computer memory device so that other

10　computer program module may access this result. In some preferred embodiments, the computer software products may include code to accept user's selection of various significance levels.

In addition, computer software products for analyzing the presence of a transcript without using mismatch intensities. The computer software product includes computer

15　program code for providing a plurality of perfect match intensity values (PM_i) and background intensity values (B_i) for a transcript, wherein each of the PM_i is paired with one of the B_i; computer program code for calculating a p value using one sided Wilcoxon's signed rank test, wherein said p value is for a null hypothesis that $\theta = a$ threshold value and an alternative hypothesis that the $\theta >$ the threshold value, where the θ

20　is a test statistic for intensity difference between the perfect match intensity values and background intensity values; and computer program code for indicating whether the

transcript is present based upon the p value; and a computer readable media for storing the codes. The testing statistic may be *median(PM$_i$-B$_i$)*. The threshold value can be zero.

In preferred embodiments, the threshold value is calculated using:

$\tau_3 = c_3\sqrt{median(PM_i)}$ where the c_3 is a constant and alternatively, the threshold value is

5 calculated using: $\tau_3 = c_3\sqrt{mean(PM_i)}$ where the c_3 is a constant.

The computer software product may include computer program code for indicating that the transcript is present, absent or marginally absent . The computer program code, when executed, may indicate the result by causing the display of the result on a display device such as a screen. Alternatively, the result may be outputted into a file.

10 In addition, the result may be temporary stored in a computer memory device so that other computer program module may access this result. In some preferred embodiments, the computer software products may include code to accept user's selection of various significance levels.

Appropriate computer code, computer systems and products are adapted to carry

15 out the present invention.

In addition, systems for determining whether a transcript is present in a biological sample are also provided. The systems include a processor; and a memory being coupled to the processor, the memory storing a plurality machine instructions that cause the processor to perform a plurality of logical steps when implemented by the processor; the

20 logical steps include the method steps of the invention.

V.   Examples.

Example 1. Table 1 and 2 list Ryder discrimination score in several sets of Latin square experiments with over 100 genes in each experiment with concentrations 0, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 1024 pM.

Table 1 . Statisticsof R_i by Concentration in pMol

For a Yeast Latin Square Data Set 9912072

Concentration	Median	Interquartile range	Minimum-maximum range
0	0.0029	[-0.0088, 0.0156]	[-0.0528, 0.3229]
0.25	0.0994	[0.0610, 0.1460]	[0.0195, 0.5016]
0.5	0.777	[0.1247, 0.2486]	[0.0468, 0.6398]
1	0.2595	[0.1789, 0.3474]	[0.0502, 0.6527]
2	0.3744	[0.3035, 0.4577]	[0.0892, 0.7533]
4	0.5037	[0.4125, 0.5717]	[0. 396, 0.7086]
8	0.6138	[0.5061, 0.6749]	[0.2608, 0.7672]
16	0.6704	[0.6057, 0.7268]	[0.4 53, 0.8166]
32	0.7315	[0.6604, 0.7739]	[0.5358, 0.8418]
64	0.7475	[0.6717, 0.7952]	[0.4562, 0.8464]
128	0.7459	[0.6792, 0.8075]	[0.5772, 0.8611]
256	0.7630	[0.6831, 0.7941]	[0.4961, 0.8665]
512	0.7354	[0.6320, 0.7885]	[0.4446, 0.8666]
1024	0.7171	[0.6276, 0.7780]	[0.3611, 0.8518]

When Ryder's discrimination score median (R_i) is below 0.7, corresponding approximately to the concentration range below 16-64 pM or so, R_i increases when the concentration of the gene increases. Beyond this range, R_i may decrease as gene concentration increases, but remains higher than 0.7. Therefore, R_i is not always an increasing function of gene concentration, especially when median(R_i) is above 0.7, but for the purpose of absolute calls, i.e., to detect the existence of a gene above a small concentration, e.g., 1 or 2 pM, Ryder's discrimination score R_i is a very good statistic to use.

Saturation is the situation when the brightness of the pixels exceeds the brightness range of the scanner. When there is saturation PM_i and MM_i can be both large and close to each other, thus Ryder's discrimination score becomes small. To prevent this situation from interfering our analysis, a first check may be necessary to determine whether there are any saturated cells, and exclude them from further analysis. If all probe pairs are saturated, the gene may be indicated as detected, i.e., set the p-value to be 0.

Table 2. Statistics of R_i by Concentration in pMol

For a Yeast Latin Square Data Set 9912072 with Human Genome Background

Concentration	Median	Interquartile range	Minimum-maximum range
0	0.0065	[-0.0058, 0.0225]	[-0.046 , 0. 47]
0.25	0.0366	[0.0 94, 0.0604]	[-0.0 50, 0.2676]
0.5	0.0589	[0.0336, 0. 073]	[-0.0082, 0.3235]

1	0.0970	[0.0698, 0. 536]	[0.0032, 0.4557]
2	0.1704	[0.1159, 0.2465]	[0.0152, 0.5834]
4	0.2638	[0.1760, 0.3602]	[0.0275, 0.6784]
8	0.4112	[0.3420, 0.4947]	[0.0871, 0.6942]
16	0.5368	[0.3807, 0.5967]	[0.1048, 0.7424]
32	0.6228	[0.5469, 0.6849]	[0. 37 , 0.7752]
64	0.6971	[0.6524, 0.7537]	[0.2847, 0.8300]
128	0.7183	[0.6588, 0.7726]	[0.3311, 0.8615]
256	0.7324	[0.6313, 0.7762]	[0.4198, 0.8612]
512	0.7252	[0.6151, 0.7842]	[0.4038, 0.8505]
1024	0.7081	[0.6168, 0.7524]	[0.4048, 0.8317]

Example 2. In a semi-blind test, 11 yeast target genes were used in a hybridization solution and the yeast genome chip YG_S98 was used. The concentration of every yeast gene was 5 pM. This was a semi-blind because the algorithm developer only knew the number of target yeast genes, but neither their names nor the number and names of bacterial spiked genes. Table 3 lists the 25 sorted p-values of absolute calls for $p < \alpha_1 = 0.05$ with the one-sided signed rank test (1). The parameter τ_1 was obtained with Equation (3c) where $c''_1 = 1.2$. The first 23 units gave the correct answer of 13 units of 11 yeast genes (YAL038W, YDL235C, YEL003W, YEL018W, YEL024W, YER161C, YFL018C, &KL193C, YLR083C, YNL259C, YPR129W) and 9 units of four bacterial spiked genes (BioB, BioC, BioDn and CreX) with a false positive. The p-value,

40

0.001602, of the unit YEL003W_at with target in hybridization the solution has a

relatively large difference with the p-value, 0.003906, of the 24th unit NNL069W_i_at

whose target is not in the hybridization solution. Therefore, if the significance level is

chosen somewhere between these two numbers, a clear cutoff can be obtained.

5

Table 3. The smallest 25 p-values for Absolute Calls in a Test with

11 Yeast Targets and 4 Bacterial Genes

Index	p-value	τ_1	Unit No.	Unit Name	Probe Pairs	P/A
1	0.000044	51.6	11	AFFX-BioB-M_at	20	P
2	0.000044	54.3	13	AFFX-BioC-5_at	20	P
3	0.000044	44.1	15	AFFX-BioC-3_at	20	P
4	0.000044	31.7	16	AFFX-BioDn-5_at	20	P
5	0.000044	91.3	18	AFFX-BioDn-3_at	20	P
6	0.000044	95.2	97	AFFX-YEL0 8w/_at	20	P
7	0.000052	40.3	10	AFFX-BioB-5_at	20	P
8	0.000052	70.8	12	AFFX-BioB-3_at	20	P
9	0.000052	58.8	21	AFFX-CreX-3_at	20	P
10	0.000070	46.6	19	AFFX-CreX-5_at	20	P
11	0.000219	173.3	6105	YFL0 8C_at	16	P

12	0.000219	96.5	5941	YER 161C_at	16	P
13	0.000219	123.5	721	YKL 193C_at	16	P
14	0.000219	191.9	131	YAL038W_at	16	P
15	0.000258	120.6	98	AFFX-YEL024w/RIP_at	20	P
16	0.000266	95.6	1243	YLR083C_at	16	P
17	0.000266	111.1	5750	YEL0 8W_at	16	P
18	0.000322	96.0	2371	YNL259C_at	16	P
19	0.000388	34.9	4773	YDL235C_at	16	P
20	0.000388	196.9	5744	YEL024W_at	16	P
21	0.000468	81.7	3873	YPR129W_at	16	P
22	0.001141	13.7	3874	YPR130C_at	16	A
23	0.001602	57.6	5766	YEL003W_at	16	P
24	0.003906	11.8	2722	NNL069W_i_at	9	A
25	0.028446	11.4	28	AFFX-BioDn-3_st	20	A

In Table 3, the column labeled Probe Pairs lists the number of probe pairs in the unit. The column labeled P/A denotes whether the corresponding target is present (P) or absent (A) in the hybridization solution.

With Ryder's discrimination score and $\tau2 = 0.02$, sorting the p-values in the ascending order, similar results were obtained and shown in Table 4 and p-values

0.009985 for YEL003W_at in the hybridization solution and 0.023438 of gMR07_3_at

not in the hybridization solution have a big gap.

Table 4. The smallest 25 p-values for Absolute Calls inaTest with Yeast Targets and

5   4 Bacterial Genes Using Ryder's Discrimination Score

Index	p-value	Unit No	. Unit Name	Probe Pairs	P/A
1	0.000044	10	AFFX-BioB-5_at	20	P
2	0.000044	12	AFFX-BioB-3_at	20	P
3	0.000044	13	AFFX-BioC-5_at	20	P
4	0.000044	15	AFFX-BioC-3_at	20	P
5	0.000044	18	AFFX-BioDn-3_at	20	P
6	0.000044	19	AFFX-CreX-5_at	20	P
7	0.000052	11	AFFX-BioB-M_at	20	P
8	0.000052	21	AFFX-CreX-3_at	20	P
9	0.000052	97	AFFX-YEL0 8w/_at	20	P
10	0.000060	16	AFFX-BioDn-5_at	20	P
11	0.000219	1243	YLR083C_at	16	P
12	0.000219	5750	YEL0 8W_at	16	P
13	0.000219	5941	YER161C_at	16	P

14	0.000219	6105	YFL018C_at	16	P
15	0.000266	131	YAL038W_at	16	P
16	0.000390	98	AFFX-YEL024w/RIP _at	20	P
17	0.000468	721	YKL193C_at	16	P
18	0.000673	3873	YPR129W_at	16	P
19	0.000805	5744	YEL024W_at	16	P
20	0.001892	4773	YDL235C_at	16	P
21	0.002617	3874	YPR130C_at	16	A
22	0.002930	2722	NNL069W_i_at	9	A
23	0.006532	2371	YNL259C_at	16	P
24	0.009985	5766	YEL003W_at	16	P
25	0.023438	8862	gMR07_3_at	8	A

Example 3. In a Latin square experiment design, 14 groups of yeast gene transcripts (8 genes per group) with different concentrations were used in 14 experiments (Table 5). In some of the data sets, human genome background was also added in the hybridization solution. These hybridization solutions were used on yeast genome chips yg_s95 and yeast test chips test_hyb.

Table 5. Concentrations in pMol of 14 Groups of Genes in 14 Experiments

Exp.	G1	G2	G3	G4	G5	G6	G7	G8	G9	G10	G11	G12	G13	G14
E1	0	0.25	0.5	1	2	4	8	16	32	64	128	256	521	1024
E2	0.25	0.5	1	2	4	8	16	32	64	28	256	512	1024	0
E3	0.5	1	2	4	8	16	32	64	128	256	512	1024	0	0.25
E4	1	2	4	8	16	32	64	128	256	512	1024	0	0.25	0.5
E5	2	4	8	16	32	64	128	256	512	1024	0	0.25	0.5	1
E6	4	8	16	32	64	128	256	512	1024	0	0.25	0.5	1	2
E7	8	16	32	64	128	256	512	1024	0	0.25	0.5	1	2	4
E8	16	32	64	128	256	512	1024	0	0.25	0.5	1	2	4	8
E10	64	128	256	512	1024	0	0.25	0.5	1	2	4	8	16	32
E11	128	256	512	1024	0	0.25	0.5	1	2	4	8	16	32	64
E12	256	512	1024	0	0.25	0.5	1	2	4	8	6	32	64	128
E13	512	1024	0	0.25	0.5	1	2	4	8	6	32	64	128	256
E14	1024	0	0.25	0.5	1	2	4	8	6	32	64	128	256	512

5   Eight genes were excluded from the analysis because of poor quality. The

remaining genes were used for analysis. Yeast genes not in the Latin square were

considered as with concentration 0. Tables 6 and 7 give the error rates by concentrations

of our rank-based algorithm using Ryder's discrimination score with $\tau_2 = 0.012$, $\alpha_1 = 0.04$,

and $\alpha_2 = 0.06$ for two Latin square data sets, one without human genome background, and

the other with human genome background. If lower false positive rate is wanted, one can

lower τ_2, or raise α_1 and/or α_2

Table 6. Error Rates of Absolute Calls for Data Set 99802

Concentration	Marginal as undetected	Marginal as detected	Type of error
0	0.0562	0.0798	false positive
0.25	0.0991	0.0811	false negative
0.5	0.0270	0.0180	false negative
1	0.0270	0.0090	false negative
2	0	0	false negative
4	0	0	false negative
8	0	0	false negative
16	0	0	false negative
32	0	0	false negative
64	0	0	false negative
128	0	0	false negative
256	0	0	false negative
512	0	0	false negative
1024	0	0	false negative

5

The column labeled by "Marginal as undetected" shows the error rates when the marginal calls are counted as undetected calls, i.e., α_1 is used as the cutoff. The column labeled by "Marginal as detected" shows the error rates when the marginal calls are counted as detected calls, i.e., α_2 is used as the cutoff.

5   Table 7. Error Rates of Absolute Calls for Data Set 99802BG

Concentration	Marginal as undetected	Marginal as detected	Type of error
0	0.0388	0.0524	false positive
0.25	0.7027	0.6937	false negative
0.5	0.5586	0.5135	false negative
1	0.3063	0.2883	false negative
2	0.0991	0.0811	false negative
4	0.0360	0.0180	false negative
8	0	0	false negative
16	0	0	false negative
32	0	0	false negative
64	0	0	false negative
128	0	0	false negative
256	0	0	false negative

512	0	0	false negative
1024	0	0	false negative

Conclusion

The present inventions provide methods and computer software products

5   for analyzing gene expression profiles. It is to be understood that the above description

is intended to be illustrative and not restrictive. Many variations of the invention will be

apparent to those of skill in the art upon reviewing the above description. By way of

example, the invention has been described primarily with reference to the use of a high

density oligonucleotide array, but it will be readily recognized by those of skill in the art

10   that other nucleic acid arrays, other methods of measuring transcript levels and gene

expression monitoring at the protein level could be used. The scope of the invention

should, therefore, be determined not with reference to the above description, but should

instead be determined with reference to the appended claims, along with the full scope of

equivalents to which such claims are entitled.

All cited references, including patent and non-patent literature, are incorporated

herein by reference in their entireties for all purposes.